Welcome to the Official Website for the 23andMe, Inc. PGS Settlement

If you purchased a PGS, "Personal Genome Service", from 23andMe.com from October 16, 2007, to November 22, 2013, you are included in a settlement and may receive cash compensation.

On November 22, 2013, the U.S. Food and Drug Administration (“FDA”) sent 23andMe a letter (the “Warning Letter”) that directed the Company to discontinue marketing the health information component of the Company’s Personal Genome Service (“PGS”). On January 13, 2014, the putative class action arbitration captioned Davis-Hudson, et al. v. 23andMe, Inc. was submitted to the American Arbitration Association and assigned Case No. 74-20-1400-0032 (the “Arbitration”). The claims asserted in the Arbitration arose out of the Warning Letter and concerned 23andMe’s PGS. Claimants allege in the Arbitration that the PGS was sold to consumers based on inaccurate or misleading information regarding the PGS specifications and capabilities, and was not sold in compliance with applicable federal and state laws.

Although the information in this website is intended to assist potential class members, it does not replace the information contained in the Class Notice or the Settlement Agreement, both of which can be downloaded from this website.

Please Note the Following Important Dates:

Case Relevant Event


An Election Form must be filed online or postmarked by

December 6, 2017

An Exclusion must be postmarked on or before

October 20, 2017

An Objection must be postmarked or delivered to the parties no later than              

October 20, 2017

The Final Approval Hearing will take place on

November 15, 2017